Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | CHRND | Q07001 | 6/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.50 |
| ▸ | CHRNG | P07510 | 2/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12148793 | 0.99 | GRIA1 (0.56) | GRIA1EPHX2FAAHCHRNDCHRNA1 | |
| SCHEMBL12148790 | 0.93 | GRIA1 (0.62) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL5817448 | 0.84 | FAAH (0.71) | GRIA1EPHX2FAAH | |
| SCHEMBL20687044 | 0.82 | GRIA1 (0.61) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL1875305 | 0.82 | GRIA1 (0.59) | GRIA1EPHX2FAAHCHRNDCHRNA1 | |
| SCHEMBL1875301 | 0.82 | GRIA1 (0.59) | GRIA1EPHX2FAAHCHRNDCHRNA1 | |
| SCHEMBL20687046 | 0.82 | GRIA1 (0.64) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL13367166 | 0.80 | EPHX2 (0.65) | EPHX2 | |
| SCHEMBL12522320 | 0.79 | EPHX2 (0.63) | EPHX2 | |
| SCHEMBL12148858 | 0.79 | EPHX2 (0.63) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | GRIA1 1430/4885EPHX2 2326/4885FAAH 1738/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | GRIA1 1827/4885EPHX2 3928/4885FAAH 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.